Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees
Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees.
Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering
In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).
Co-founder Dr. George Church visited Qihan to lead SAB meetings
On October 23, 2019, Dr. George Church visited Qihan, and he learned about the team’s research progress and gave a scientific speech on cutting-edge gene-editing technology.
Qihan Biotech Raises USD 25.5 million in Series A+ Financing
On September 23, 2019, Hangzhou Qihan Biotechnology Co., Ltd. announced the completion of USD 25.5 million Series A+ financing.
Qihan Biotech named in MIT Technology Review List of 50 Smartest Companies in China 2019
MIT Technology Review released their list of the "50 Smartest Companies in China 2019" . Qihan Bio was named on the TR50 list.
Inaugural Genome Engineering and Regenerative Medicine International Conference
Qihan Biotech held its first Genome Editing and Regenerative Medicine Summit in the G20 venue, Hangzhou International Expo Center, on October 21, 2018.
Committed to addressing the global shortage of transplantable organs, Qihan Biotech Raises USD 7.8 Million in Series A Financing
Hangzhou Qihan Biotech has completed its Series A financing of USD 7.8 million led by Sequoia Capital China.